Hammody 2015.

Study characteristics
Methods	Design: parallel Duration: 12 weeks Assessment: baseline, week 4, week 8, post‐intervention Country: Iraq
Participants	Pain condition: fibromyalgia Population: adults with fibromyalgia Minimum pain intensity: no Inclusion criteria Patients with fibromyalgia fulfilling the Wolfe 2010 criteria Exclusion criteria Inflammatory conditions and cardiovascular problems Total participants randomised: 123 Age in years (mean, SD): NR Gender: NR Pain duration in years (mean, SD): NR
Interventions	Pregabalin 75 mg n = 62 Anticonvulsant Fixed dose, no titration Amitriptyline 25 mg n = 61 TCA Fixed dose, no titration
Outcomes	Pain intensity Quality of life
Missing data methods	NR
Funding source	NR
Conflicts of interest	NR
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation methods not specified
Allocation concealment (selection bias)	Unclear risk	Allocation procedures not specified
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	States double‐blind, but no information regarding blinding procedures
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Self‐reported outcomes from participants, but unsure of blinding procedures
Incomplete outcome data (attrition bias) All outcomes	High risk	High attrition, analysis of per‐protocol population Attrition Total: 45/123 (36.6%) Attrition per arm NR
Selective reporting (reporting bias)	Unclear risk	No protocol or trial registration found
Other bias	High risk	Poorly reported ‐ mistakes throughout document, figures not really adding up and tables wrongly titled